Science News » Bench-to-Bedside: NIMH Research Leading to Brexanolone, First-Ever Drug Specifically for Postpartum Depression

FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.

Source: National Institute of Mental Health - March 20, 2019 Category: Psychiatry Authors: Claire Cole Source Type: news